After creating two new R&D units and simultaneous commercial units to run alongside them, with a new and controversial scientist taking up the cancer research reins, the changes and departures keep coming from AstraZeneca.
Today, Bloomberg reports that Sean Bohen, M.D., Ph.D., CMO and EVP of global medicines development, is out the door, following closely in the footsteps of Bahija Jallal, Ph.D., former head of its biologics arm MedImmune, now CEO of Immunocore, as well as portfolio strategy chief Mark Mallon.
The R&D and commercial changes announced last week were a reaction to these departures and saw José Baselga, M.D., Ph.D., run its newly formed cancer-focused unit. He had been physician-in-chief at Memorial Sloan-Kettering but was forced out in the fall over allegations he was paid renumeration from biopharmas that were not properly disclosed.
Mene Pangalos, Ph.D., who was previously responsible for the company’s Innovative Medicines and Early Development Biotech Unit, now runs a second, nononcology unit.
Bohen now becomes the latest high-profile executive to leave the company. The British-based pharma confirmed to FierceBiotech that Bohen will be leaving but won’t be going until a successor is found. The former Genentech executive did not say where he would be setting his sights on next, but the company said he was key in the company’s growth, and that he will leave “eventually,” although a direct successor is not yet being sought.
This comes amid a mixed time for AstraZeneca, with its CEO Pascal Soriot also endlessly speculated to be heading for the exit, something however he continuously denies, and a plethora of trial setbacks over the years, with cancer becoming a brighter spot but still being hit by some late-stage failures.
By Ben Adams
Source: Fierce Biotech
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
